44-
Baselga J, Im S-A, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiello-
Gruszfeld A, Pistilli B, Tseng L-M, Hurvitz S, Masuda N, Corté s J, De Laurentiis M,
Arteaga CL, Jiang Z, Jonat W, Hachemi S, Le Mouhaë r S, Di Tomaso E, Urban P,
Massacesi C, Campone M. PIK3CA status in circulating tumor DNA (ctDNA) predicts
efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with
endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the
randomized, phase III BELLE-2 trial. SABCS, 2015, S6-01.
20
